Moderna Is Developing Four COVID-19 Vaccine Variants
Moderna (MRNA +6.3%) is developing four vaccines against COVID-19 variants of concern, three of which have been administered in phase 2/3 clinical trials.
Two of them are for, respectively, the beta and delta variants.
The third combines the beta-specific variant vaccine and mRNA-1273, Moderna's original COVID-19 vaccine.
The fourth is another combination targeting the beta and variants.
In an R&D day presentation today, Moderna also highlighted data surrounding its booster dose study, which showed it significantly increased neutralizing titers.
Moderna is awaiting FDA Emergency Use Authorization for a booster dose. It completed its submission to the agency last week.
The company said it has completed enrollment in the 6 years old to <12 years old cohort of the Phase 2 KidCOVE study of mRNA-1273 with 4K participants.
Moderna also noted that a phase 1 study of mRNA-1283, its next-generation COVID-19 vaccine candidate, is fully enrolled.
Moderna is currently awaiting action from the FDA on its BLA submission for full approval of its mRNA-1273 vaccine in adults 18 and older.
Note, I do not know the photographer.
Moderna Is Developing Four COVID-19 Vaccine Variants
Moderna (MRNA +6.3%) is developing four vaccines against COVID-19 variants of concern, three of which have been administered in phase 2/3 clinical trials.
Two of them are for, respectively, the beta and delta variants.
The third combines the beta-specific variant vaccine and mRNA-1273, Moderna's original COVID-19 vaccine.
The fourth is another combination targeting the beta and variants.
In an R&D day presentation today, Moderna also highlighted data surrounding its booster dose study, which showed it significantly increased neutralizing titers.
Moderna is awaiting FDA Emergency Use Authorization for a booster dose. It completed its submission to the agency last week.
The company said it has completed enrollment in the 6 years old to <12 years old cohort of the Phase 2 KidCOVE study of mRNA-1273 with 4K participants.
Moderna also noted that a phase 1 study of mRNA-1283, its next-generation COVID-19 vaccine candidate, is fully enrolled.
Moderna is currently awaiting action from the FDA on its BLA submission for full approval of its mRNA-1273 vaccine in adults 18 and older.
Note, I do not know the photographer.